20
Participants
Start Date
May 31, 2008
Primary Completion Date
January 31, 2009
Study Completion Date
July 31, 2011
LBH589
LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
Capecitabine
Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Lapatinib
Lapatinib, 1000 mg PO daily will be added to this combination.
Tennessee Oncology, PLLC, Nashville
Collaborators (1)
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER